We used SIPS agents and validated the role of p300 in lymphoblastoid cell lines (LCLs) derived from patients affected by a rare genetic disorder with pathogenetic variants in EP300, the gene coding for p300, and healthy donors (HD). This evidence concerns the gene EP300 and hereditary disease.